PK 101
Alternative Names: PK-101; PK-101-001/PK-101-002Latest Information Update: 28 Mar 2022
At a glance
- Originator PMG Pharm Co Ltd
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Osteoarthritis
- No development reported Arthritis
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Arthritis(In volunteers) in South Korea
- 20 May 2021 Phase-III clinical trials in Osteoarthritis (In adults, In the elderly) in South Korea (unspecified route) (NCT04858659)
- 29 Apr 2021 PMG Pharm plans a phase III trial for Osteoarthritis of knee in South Korea (NCT04858659)